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Abstract
Biomarkers abound in many areas of clinical research, and often investigators are interested
in combining them for diagnosis, prognosis, or screening. In many applications, the true posi-
tive rate for a biomarker combination at a prespecified, clinically acceptable false positive rate
is the most relevant measure of predictive capacity. We propose a distribution-free method
for constructing biomarker combinations by maximizing the true positive rate while constrain-
ing the false positive rate. Theoretical results demonstrate desirable properties of biomarker
combinations produced by the new method. In simulations, the biomarker combination pro-
vided by our method demonstrated improved operating characteristics in a variety of scenarios
when compared with alternative methods for constructing biomarker combinations. Biomarker
combinations; False positive rate; Sensitivity; Specificity; True positive rate.
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1 Introduction
As the number of available biomarkers has grown, so has the interest in combining them for the
purposes of diagnosis, prognosis, or screening. Over the past decade, much work has been done to
develop methods for constructing biomarker combinations by targeting measures of performance,
including those related to the receiver operating characteristic, or ROC, curve. This is in contrast
to more traditional methods that construct biomarker combinations by optimizing general global
fit criteria, such as the maximum likelihood approach. While methods to construct both linear and
nonlinear combinations have been proposed, linear biomarker combinations are more common than
nonlinear combinations, due to their greater interpretability and ease of construction (Wang and
Chang, 2011; Hsu and Hsueh, 2013).
Although the area under the ROC curve, the AUC, is arguably the most popular way to sum-
marize the ROC curve, there is often interest in identifying a biomarker combination with a high
true positive rate (TPR), the proportion of correctly classified diseased individuals, while setting
the false positive rate (FPR), the proportion of incorrectly classified nondiseased individuals, at
some clinically acceptable level. A common practice among applied researchers is to construct
linear biomarker combinations using logistic regression, and then calculate the TPR for the pre-
specified FPR, e.g., Moore et al. (2008). While methods for constructing biomarker combinations
by maximizing the AUC or the partial AUC have been developed, these methods do not directly
target the TPR for a specified FPR.
We propose a distribution-free method for constructing linear biomarker combinations by max-
imizing the TPR while constraining the FPR. We demonstrate desirable theoretical properties
of the resulting combination, and provide empirical evidence of good small-sample performance
through simulations. To illustrate our method, we consider data from a prospective study of dia-
betes mellitus in 532 adult women with Pima Indian heritage (Smith et al., 1988). Several variables
were measured for each participant, and criteria from the World Health Organization were used to
identify women who developed diabetes. A primary goal of the study was to predict the onset of
diabetes within five years.
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2 Background
2.1 ROC Curve and Related Measures
The ROC curve provides a means to evaluate the ability of a biomarker or, equivalently, biomarker
combination Z to identify individuals who have or will experience a binary outcomeD. For example,
in a diagnostic setting, D denotes the presence or absence of disease and Z may be used to identify
individuals with the disease. The ROC curve provides information about how well the biomarker
discriminates between individuals who have or will experience the outcome, that is, the cases,
and individuals who do not have or will not experience the outcome, that is, the controls (Pepe,
2003). Mathematically, if larger values of Z are more indicative of having or experiencing the
outcome, for each threshold δ we can define the TPR as P (Z > δ | D = 1) and the FPR as
P (Z > δ | D = 0) (Pepe, 2003). For a given δ, the TPR is also referred to as the sensitivity, and
one minus the specificity equals the FPR (Pepe, 2003). The ROC curve is a plot of the TPR versus
the FPR as δ ranges over all possible values; as such, it is non-decreasing and takes values in the
unit square (Pepe, 2003). A perfect biomarker has an ROC curve that reaches the upper left corner
of the unit square, and a useless biomarker has an ROC curve on the 45-degree line (Pepe, 2003).
The most common summary of the ROC curve is the AUC, the area under the ROC curve.
The AUC ranges between 0.5 for a useless biomarker and 1 for a perfect biomarker (Pepe, 2003).
The AUC has a probabilistic interpretation: it is the probability that the biomarker value for a
randomly chosen case is larger than that for a randomly chosen control, assuming that higher
biomarker values are more indicative of having or experiencing the outcome (Pepe, 2003). Both the
ROC curve and the AUC are invariant to monotone increasing transformations of the biomarker
Z (Pepe, 2003).
The AUC summarizes the entire ROC curve, but in many situations it is more appropriate
to only consider certain FPR values. For example, screening tests require a very low FPR, while
diagnostic tests for fatal diseases may allow for a slightly higher FPR if the corresponding TPR
is very high (Hsu and Hsueh, 2013). Such considerations led to the development of the partial
AUC, the area under the ROC curve over some range (t0, t1) of FPR values (Pepe, 2003). Rather
than considering a range of FPR values, there may be interest in fixing the FPR at a single value,
determining the corresponding threshold δ, and evaluating the TPR for that threshold. As opposed
to the AUC and the partial AUC, this method returns a single classifier, or decision rule, which
may appeal to researchers seeking a tool for clinical decision-making.
3
2.2 Biomarker Combinations
Many methods to combine biomarkers have been proposed, and they can be divided into two
categories. The first includes indirect methods that seek to optimize a measure other than the
performance measure of interest, while the second category includes direct methods that optimize
the target performance measure. We focus on the latter.
Targeting the entire ROC curve (that is, constructing a combination that produces an ROC
curve that dominates the ROC curve for all other linear combinations at all points) is very chal-
lenging and is only possible under special circumstances. Su and Liu (1993) demonstrated that,
when the vector X of biomarkers has a multivariate normal distribution conditional on D with pro-
portional covariance matrices, it is possible to identify the linear combination that maximizes the
TPR uniformly over the entire range of FPRs; this linear combination is Fisher’s linear discriminant
function.
McIntosh and Pepe (2002) used the Neyman-Pearson lemma to demonstrate optimality (in
terms of the ROC curve) of the likelihood ratio function and, consequently, of the risk score
P (D = 1|X = x) and monotone transformations of P (D = 1|X = x). Thus, if the biomark-
ers are conditionally multivariate normal and the D-specific covariance matrices are equal, the
optimal linear combination dominates not just every other linear combination, but also every
nonlinear combination. This results from the fact that in this case, the linear logistic model
logit{P (D = 1|X = x)} = θ>x holds for some p-dimensional θ, where p is the dimension of X. If
the covariance matrices are proportional but not equal, the likelihood ratio is a nonlinear function
of the biomarkers, as shown in the Appendix A for p = 2, and the optimal biomarker combination
with respect to the ROC curve is nonlinear.
In general, there is no linear combination that dominates all others in terms of the TPR over
the entire range of FPR values (Su and Liu, 1993; Anderson and Bahadur, 1962). Thus, methods to
optimize the AUC have been proposed. When the biomarkers are conditionally multivariate normal
with nonproportional covariance matrices, Su and Liu (1993) gave an explicit form for the best linear
combination with respect to the AUC. Others have targeted the AUC without any assumption on
the distribution of the biomarkers; many of these methods rely on smooth approximations to the
empirical AUC, which involves indicator functions (Ma and Huang, 2007; Fong, Yin, and Huang,
2016; Lin et al., 2011).
Acknowledging that often only a range of FPR values is of interest clinically, methods have been
4
proposed to target the partial AUC for some FPR range (t0, t1). Some methods make parametric
assumptions about the joint distribution of the biomarkers (Yu and Park, 2015; Hsu and Hsueh,
2013; Yan et al., 2018) while others do not (Wang and Chang, 2011; Komori and Eguchi, 2010; Yan
et al., 2018). The latter group of methods generally uses a smooth approximation to the partial
AUC, similar to some of the methods that aim to maximize the AUC (Wang and Chang, 2011;
Komori and Eguchi, 2010; Yan et al., 2018). One challenge faced in partial AUC maximization is
that for narrow intervals, that is, when t0 is close to t1, the partial AUC is often very close to 0,
which can make optimization difficult (Hsu and Hsueh, 2013).
Some work in constructing biomarker combinations by maximizing the TPR has been done for
conditionally multivariate normal biomarkers. In this setting, procedures for constructing a linear
combination that maximizes the TPR for a fixed FPR (Anderson and Bahadur, 1962; Gao et al.,
2008) as well as methods for constructing a linear combination by maximizing the TPR for a range
of FPR values (Liu, Schisterman, and Zhu, 2005) have been proposed. Importantly, in the method
proposed by Liu, Schisterman, and Zhu (2005), the range of FPR values over which the fitted
combination is optimal may depend on the combination itself; that is, the range of FPR values may
be determined by the combination and so may not be fixed in advance. Thus, this method does not
optimize the TPR for a prespecified FPR. Baker (2000) proposed a flexible nonparametric method
for combining biomarkers by optimizing the ROC curve over a narrow target region of FPR values.
However, this method is not well-suited to situations in which more than a few biomarkers are to
be combined.
An important benefit of constructing linear biomarker combinations by targeting the perfor-
mance measure of interest is that the performance of the combination will be at least as good as the
performance of the individual biomarkers (Pepe, Cai, and Longton, 2006). Indeed, several authors
have recommended matching the objective function to the performance measure, i.e., constructing
biomarker combinations by optimizing the relevant measure of performance (Hwang et al., 2013;
Liu, Schisterman, and Zhu, 2005; Wang and Chang, 2011; Ricamato and Tortorella, 2011). To that
end, we propose a distribution-free method to construct biomarker combinations by maximizing
the TPR for a given FPR.
Figure 1 illustrates the importance of targeting the measure of interest in constructing biomarker
combinations. In this example, combinations of three biomarkers are constructed by (i) maximizing
the logistic likelihood, (ii) maximizing the AUC via the optAUC package in R (i.e., the method
of Huang, Qin, and Fang (2011)), and (iii) maximizing the TPR for an FPR of 20% using the
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proposed method. The ROC curves for the three combinations differ markedly near the prespecified
FPR of 20%. In particular, the TPRs at an FPR of 20% for the three combinations are 18.0%,
24.0%, and 34.0% for maximum likelihood, AUC optimization, and maximization of the TPR for
a given FPR, respectively. This example highlights the utility of methods that target the TPR for
a specific FPR as opposed to methods that target other measures.
Figure 1: Biomarker combinations obtained by targeting different measures. In this illustrative
example, there is interest in the TPR for an FPR of 20%. Combinations of three biomark-
ers were constructed in training data (400 cases and 400 controls) and evaluated in a large test
dataset (10,000 cases and 10,000 controls). Two of the biomarkers, X1 and X2, were distributed
as conditional bivariate lognormal random variables such that, among controls, E(log(X1)) =
1.1, E(log(X2)) = 1.1, V ar(log(X1)) = 0.04, V ar(log(X2)) = 0.5, Cov(log(X1), log(X2)) = 0.09
and, among cases, E(log(X1)) = 1, E(log(X2)) = 1, V ar(log(X1)) = 0.05, V ar(log(X2)) =
0.05, Cov(log(X1), log(X2)) = 0.015. The third biomarker, X3, was distributed as an inde-
pendent lognormal random variable such that, among both cases and controls, E(log(X3)) =
1.65, V ar(log(X3)) = 4.66. The combinations were constructed by maximizing the TPR for an
FPR of 20% (“Optimal TPR”; green), by maximizing the logistic likelihood (“Logistic Regres-
sion”; blue), and by maximizing the AUC (“Optimal AUC”; red). The gray line indicates the ROC
curve for a useless marker (FPR and TPR are equal), the black dashed line denotes an FPR of
20%, and the dot-dashed lines indicate the TPRs for an FPR of 20%. This figure appears in color
in the electronic version of this article.
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3 Methodology
3.1 Description
Cases are denoted by the subscript 1 and controls are denoted by the subscript 0. Let X1i denote
the vector of biomarkers for the ith case, and let X0j denote the vector of biomarkers for the j
th
control.
We propose constructing a linear biomarker combination of the form θ>X for a p-dimensional
X by maximizing the TPR when the FPR is below some prespecified, clinically acceptable value t.
We define the true and false positive rates for a given X as a function of θ and δ:
TPR(θ, δ) = P (θ>X > δ|D = 1), FPR(θ, δ) = P (θ>X > δ|D = 0).
Since the true and false positive rates for a given combination θ and threshold δ are invariant to
scaling of the parameters (θ, δ), we must restrict (θ, δ) to ensure identifiability. Specifically, we
constrain ||θ|| = 1 as in Fong, Yin, and Huang (2016). For any fixed t ∈ (0, 1), we can consider
(θt, δt) ∈ arg max
(θ,δ)∈Ωt
TPR(θ, δ),
where Ωt = {θ ∈ Rp, δ ∈ R : ||θ|| = 1,FPR(θ, δ) ≤ t}. This provides the optimal combina-
tion θt and threshold δt. We define (θt, δt) to be an element of arg max(θ,δ)∈Ωt TPR(θ, δ), where
arg max(θ,δ)∈Ωt TPR(θ, δ) may be a set.
Of course, in practice, the true and false positive rates are unknown, so θt and δt cannot be
computed. We can replace these unknowns by their empirical estimates,
ˆTPRn1(θ, δ) =
1
n1
n1∑
i=1
1(θ>X1i > δ), ˆFPRn0(θ, δ) =
1
n0
n0∑
j=1
1(θ>X0j > δ),
where n1 is the number of cases and n0 is the number of controls, giving the total sample size
n = n1 + n0. We can then define
(θˆt, δˆt) ∈ arg max
(θ,δ)∈Ωˆt,n0
ˆTPRn1(θ, δ)
where Ωˆt,n0 = {θ ∈ Rp, δ ∈ R : ||θ|| = 1, ˆFPRn0(θ, δ) ≤ t}. It is possible to conduct a grid
search over (θ, δ) to perform this constrained optimization, though this becomes computationally
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demanding when combining more than two or three biomarkers.
Since the objective function involves indicator functions, it is not a smooth function of the
parameters (θ, δ) and thus not amenable to derivative-based methods. However, smooth approxi-
mations to indicator functions have been used for AUC maximization (Ma and Huang, 2007; Fong,
Yin, and Huang, 2016; Lin et al., 2011). One such smooth approximation is 1(w > 0) ≈ Φ(w/h),
where Φ is the standard normal distribution function, and h is a tuning parameter representing
the trade-off between approximation accuracy and estimation feasibility such that h tends to zero
as the sample size grows (Lin et al., 2011). We can use this smooth approximation to implement
the method described above, writing the smooth approximations to the empirical true and false
positive rates as
˜TPRn1(θ, δ) =
1
n1
n1∑
i=1
Φ
(
θ>X1i − δ
h
)
, ˜FPRn0(θ, δ) =
1
n0
n0∑
j=1
Φ
(
θ>X0j − δ
h
)
.
Thus, we propose to compute
(θ˜t, δ˜t) ∈ arg max
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ), (1)
where Ω˜t,n0 = {θ ∈ Rp, δ ∈ R : ||θ|| = 1, ˜FPRn0(θ, δ) ≤ t}. Since both ˜TPRn1 and ˜FPRn0 are
smooth functions, we can use gradient-based methods that incorporate the necessary constraints,
e.g., Lagrange multipliers. In particular, (θ˜t, δ˜t) can be obtained using existing software for con-
strained optimization of smooth functions, such as the Rsolnp package in R. An R package including
code for our method based on Rsolnp, maxTPR, is available on CRAN. Other details related to im-
plementation, including the choice of tuning parameter h, are discussed below.
3.2 Asymptotic Properties
We present a theorem establishing that, under certain conditions, the combination obtained by
optimizing the smooth approximation to the empirical TPR while constraining the smooth approx-
imation to the empirical FPR has desirable operating characteristics. In particular, its FPR is
bounded almost surely by the acceptable level t in large samples. In addition, its TPR converges
almost surely to the supremum of the TPR over the set where the FPR is constrained. We focus
on the operating characteristics of (θ˜t, δ˜t) since these are of primary interest to clinicians.
Rather than enforcing (θ˜t, δ˜t) to be a strict maximizer, in the theoretical study below we allow
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it to be a near-maximizer of ˜TPRn1(θ, δ) within Ω˜t,n0 in the sense that
˜TPRn1(θ˜t, δ˜t) ≥ sup
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ)− an ,
where an is a decreasing sequence of positive real numbers tending to zero. This provides some flex-
ibility to accommodate situations in which a strict maximizer either does not exist or is numerically
difficult to identify.
Before stating our key theorem, we give the following conditions.
(1) Observations are randomly sampled conditional on disease status D, and the group sizes tend
to infinity proportionally, in the sense that n = n1 + n0 →∞ and n1/n0 → ρ ∈ (0, 1).
(2) For each d ∈ {0, 1}, observations Xdi, i = 1, 2, . . . , nd, are independent and identically dis-
tributed p-dimensional random vectors with distribution function Fd.
(3) For each d ∈ {0, 1}, no proper linear subspace S ⊂ Rp is such that P (X ∈ S | D = d) = 1.
(4) For each d ∈ {0, 1}, the distribution and quantile functions of θ>X given D = d are globally
Lipschitz continuous uniformly over θ ∈ Rp such that ‖θ‖ = 1.
(5) The map (θ, δ) 7→ TPR(θ, δ) is globally Lipschitz continuous over Ω = {θ ∈ Rp, δ ∈ R :
||θ|| = 1}.
Theorem 1. Under conditions (1)–(5), for every fixed t ∈ (0, 1), we have that
(a) lim supn FPR(θ˜t, δ˜t) ≤ t almost surely; and
(b) |TPR(θ˜t, δ˜t)− sup(θ,δ)∈Ωt TPR(θ, δ)| tends to zero almost surely.
The proof of Theorem 1 is given in Appendix B. The proof relies on two lemmas, also in
Appendix B. Lemma 1 demonstrates almost sure convergence to zero of the difference between
the supremum of a function over a fixed set and the supremum of the function over a stochastic
set that converges to the fixed set in an appropriate sense. Lemma 2 establishes the almost sure
uniform convergence to zero of the difference between the FPR and the smooth approximation
to the empirical FPR and the difference between the TPR and the smooth approximation to the
empirical TPR. The proof of Theorem 1 demonstrates that Lemma 1 holds for the relevant function
and sets, relying in part on the conclusions of Lemma 2. The conclusions of Lemmas 1 and 2 then
demonstrate the claims of Theorem 1.
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3.3 Implementation Details
Certain considerations must be addressed to implement the proposed method, including the choice
of tuning parameter h and starting values (θ˜, δ˜) for the optimization routine. In using similar
methods to maximize the AUC, Lin et al. (2011) proposed using h = σ˜n−1/3, where σ˜ is the sample
standard error of θ˜
>
X. In simulations, we considered both h = σ˜n−1/3 and h = σ˜n−1/2 and found
similar behavior for the convergence of the optimization routine. Thus, we use h = σ˜n−1/2. We
must also identify initial values (θ˜, δ˜) for our procedure. As done in Fong, Yin, and Huang (2016),
we use normalized estimates from robust logistic regression, which is described in greater detail
below. Based on this initial value θ˜, we choose δ˜ such that ˜FPRn0(θ˜, δ˜) = t. In addition, we have
also found that when ˜FPRn0 is bounded by t, the performance of the optimization routine can
be poor. Thus, we introduce another tuning parameter, α, which allows for a small amount of
relaxation in the constraint on the smooth approximation to the empirical FPR, imposing instead
˜FPRn0(θ, δ) ≤ t+α. Since the effective sample size for the smooth approximation to the empirical
FPR is n0, we chose to scale α with n0, and have found α = 1/(2n0) to work well.
Our method involves computing the gradient of the smooth approximations to the true and
false positive rates defined above, which is fast regardless of the number of biomarkers involved.
This is in contrast with methods that rely on brute force (e.g., grid search), which typically become
computationally infeasible for combinations of more than two or three biomarkers. However, we
note that for any method, the risk of overfitting is expected to grow as the number of biomarkers
increases relative to the sample size. We emphasize that our method does not impose constraints
on the distribution of the biomarkers that can be included, except for weak conditions that allow
us to establish its large-sample properties.
4 Simulations
4.1 Bivariate Normal Biomarkers with Contamination
First, we considered bivariate normal biomarkers with contamination, similar to a scenario described
by Croux and Haesbroeck (2003). In particular, we considered a setting where two biomarkers
(X1, X2) were independently normally distributed with mean zero and variance one. D was then
defined as D = 1(2X1 + 2X2 + ζ > 0), where ζ was distributed as a logistic random variable
with location parameter zero and scale parameter one. Next, the sample was contaminated by
a set of points with D = 0, X1 = 6, and X2 = 6. We consider simulations where the training
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set consisted of 800 or 1600 “typical” observations and 50 or 100, respectively, contaminating
observations (this yielded a disease prevalence of approximately 47%). The test set consisted of 106
“typical” observations and 62,500 contaminating observations. The maximum acceptable FPR, t,
was 0.2 or 0.3. We performed 1000 simulations.
We considered five approaches: (1) logistic regression, (2) the robust logistic regression method
proposed by Bianco and Yohai (1996), (3) grid search, (4) the method proposed by Su and Liu
(1993) and (5) the proposed method. As discussed above, the method proposed by Su and Liu
(1993) yields a combination with maximum AUC when the biomarkers have a conditionally mul-
tivariate normal distribution. We did not consider the optimal AUC method proposed by Huang,
Qin, and Fang (2011) as the implementation provided in R is too slow for use in simulations (and,
as illustrated in Figure 1, may not yield a combination with optimal TPR). While the methods
recently proposed by Yan et al. (2018) to optimize the partial AUC are compelling and may yield
a combination with high TPR at the specified FPR value, implementation of their method, partic-
ularly the nonparametric kernel-based method, is non-trivial, and so is not included here. Finally,
the method of Liu, Schisterman, and Zhu (2005), discussed above, may also yield a combination
with high TPR at a particular FPR. However, given the shortcomings of this method described
above (namely, that the range of FPRs over which the combination is optimal cannot be fixed in
advanced and the biomarkers are assumed to have a conditionally multivariate normal distribu-
tion), we do not include this as a comparison method. Above all, none of these methods specifically
target the TPR for a specified FPR which, as indicated by Figure 1, may lead to combinations
with reduced TPR at the specified FPR.
We focused on evaluating the operating characteristics of the fitted combination rather than
the biomarker coefficients as the former is typically of primary interest. In particular, we evaluated
the TPR in the test data for FPR = t in the test data. In other words, for each combination,
the threshold used to calculate the TPR in the test data was chosen such that the FPR in the
test data was equal to t. Evaluating the TPR in this way puts the combinations on equal footing
in terms of the FPR, and so allows a fair comparison of the TPR. We evaluated the FPR of the
fitted combinations in the test data using the thresholds estimated in the training data, i.e., the
(1− t)th quantile of the fitted biomarker combination among controls in the training data. While
we could have used the estimate of δt provided by our method in the evaluation, we found improved
performance (that is, better control of the FPR) when re-estimating the threshold based on the
fitted combination in the training data.
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Table 1: Mean TPR and FPR and corresponding standard deviation (in parentheses) in the test
data across 1000 simulations for contaminated data with two biomarkers. The TPR is based on the
threshold corresponding to an FPR of t in the test data whereas the FPR is based on the thresholds
estimated in the training data. n, size of the training dataset; t, acceptable FPR; TPR, true positive
rate; FPR, false positive rate; GLM, standard logistic regression; rGLM, robust logistic regression;
sTPR, proposed method. All numbers are percentages.
n Measure Method
GLM rGLM Grid Search Su & Liu sTPR
t = 0.20
800 TPR 52.7 (15.9) 55.8 (15.1) 72.5 (0.9) 53.6 (15.6) 72.0 (4.5)
FPR 20.4 (1.4) 20.4 (1.4) 20.6 (1.3) 20.4 (1.4) 20.4 (1.3)
1600 TPR 57.5 (13.2) 60.0 (12.1) 72.7 (0.5) 58.3 (12.8) 72.8 (0.5)
FPR 20.3 (1.0) 20.3 (1.0) 20.4 (1.0) 20.3 (1.0) 20.3 (1.0)
t = 0.30
800 TPR 68.5 (14.3) 71.4 (13.6) 86.0 (0.5) 69.3 (13.9) 86.0 (1.2)
FPR 30.6 (1.8) 30.6 (1.8) 30.6 (1.8) 30.6 (1.8) 30.4 (1.8)
1600 TPR 74.0 (11.5) 76.1 (10.3) 86.1 (0.3) 74.7 (11.1) 86.1 (0.3)
FPR 30.4 (1.3) 30.3 (1.3) 30.4 (1.3) 30.4 (1.3) 30.2 (1.3)
Table 1 summarizes the results. For both sample sizes and FPR thresholds, all methods ad-
equately controlled the FPR, while for the TPR, the proposed method outperformed logistic re-
gression, robust logistic regression, and the method of Su and Liu (1993). Furthermore, the results
from the proposed method were comparable to those from the grid search, which may be regarded
as a performance reference but is infeasible for more than two or three biomarkers.
4.2 Conditionally Multivariate Lognormal Biomarkers
We also considered simulations with conditionally multivariate lognormal biomarkers (Mishra,
2019). In particular, we considered three biomarkers (X1, X2, X3). Among controls, log(X1) and
log(X2) had a bivariate normal distribution with E(log(X1)) = 1.1, E(log(X2)) = 1.1, V ar(log(X1)) =
0.04, V ar(log(X2)) = 0.5 and Cov(log(X1), log(X2)) = 0.09. Among cases, log(X1) and log(X2) had
a bivariate normal distribution with E(log(X1)) = 1, E(log(X2)) = 1, V ar(log(X1)) = 0.05, V ar(log(X2)) =
0.05 and Cov(log(X1), log(X2)) = 0.015. The third biomarker, X3 was simulated from an indepen-
dent lognormal distribution with E(log(X3)) = 1.65 and V ar(log(X3)) = 4.66 among both cases
and controls. Given the performance of the method of Su and Liu (1993) and the performance
of the proposed method relative to grid search observed above (and the computational challenges
of implementing grid search for three biomarkers), we considered three methods here: (1) logistic
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Table 2: Mean TPR and FPR and corresponding standard deviation (in parentheses) in the test
data across 1000 simulations for three conditionally lognormal biomarkers and t = 0.30. The TPR
is based on the threshold corresponding to an FPR of t in the test data whereas the FPR is based
on the thresholds estimated in the training data. n, size of the training dataset; t, acceptable FPR;
TPR, true positive rate; FPR, false positive rate; GLM, standard logistic regression; rGLM, robust
logistic regression; sTPR, proposed method. All numbers are percentages.
n Measure Method
GLM rGLM sTPR
800 TPR 34.1 (6.0) 34.1 (6.0) 41.5 (5.7)
FPR 30.3 (2.3) 30.3 (2.3) 31.2 (2.4)
1600 TPR 34.7 (4.2) 34.7 (4.2) 41.9 (4.9)
FPR 30.2 (1.6) 30.2 (1.6) 30.7 (1.7)
regression, (2) robust logistic regression, and (3) the proposed method. Although neither logistic
regression nor robust logistic regression performed particularly well in the simulations in Section
4.1, these methods represent the most commonly used approach for constructing biomarker com-
binations and the method used to provide starting values for the proposed method, respectively.
Thus, it was important to include them here.
The maximum acceptable FPR, t, was 0.2 and 1000 simulations were performed. The training
data consisted of either 400 cases and 400 controls, or 800 cases and 800 controls. The test data
consisted of 106 observations. The TPR and FPR were evaluated as described above. We present
the results in Table 2. All three methods did well in controlling the FPR at the specified value.
Furthermore, the proposed method substantially outperformed logistic regression and robust logistic
regression: the mean TPR based on the proposed method was at least 20% larger than the mean
TPRs from logistic regression and robust logistic regression.
4.3 Bivariate Normal Biomarkers and Bivariate Normal Mixture Biomarkers
The above simulations demonstrate superiority of our approach relative to alternative methods
in particular scenarios. We conducted further simulations to demonstrate the feasibility of our
approach in other settings (for instance, small sample size, small and large prevalence, and low
FPR cutoffs) relative to logistic regression and robust logistic regression.
We considered simulations with and without outliers in the data-generating distribution, and
simulated data under a model similar to that used by Fong, Yin, and Huang (2016). We considered
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two biomarkers X1 and X2 constructed as X1
X2
 = (1−∆)× Z0 + ∆× Z1,
where ∆ was a Bernoulli random variable with success probability pi = 0.05 when outliers were
simulated and pi = 0 otherwise, and Z0 and Z1 were independent bivariate normal random variables
with mean zero and respective covariance matrices
0.2×
 1 0.9
0.9 1
 , 2×
 1 0
0 1
 .
D was then simulated as a Bernoulli random variable with success probability f {β0 + 4X1 − 3X2
−0.8(X1 −X2)3
}
. We considered two f functions: f1(v) = expit(v) = e
v/(1 + ev) and a piecewise
logistic function,
f2(v) = 1(v < 0)× 1
1 + e−v/3
+ 1(v ≥ 0)× 1
1 + e−3v
.
We varied β0 to reflect varying prevalences, with a prevalence of approximately 50–60% for β0 =
0, 16–18% for β0 < 0, and 77–82% for β0 > 0. We considered t = 0.05, 0.1, and 0.2. A plot
illustrating the data-generating distribution with f = f1 and β0 = 0, with and without outliers, is
given in Appendix D.
The training data consisted of 200, 400, or 800 observations while the test set included 106
observations. The TPR and FPR were evaluated as described above. The results are presented
in Appendix C. When no outliers were present, the proposed method was comparable to logistic
regression and robust logistic regression in terms of both the TPR and FPR. In the presence of
outliers, robust logistic regression tended to provide combinations with higher TPRs than did lo-
gistic regression, and the TPRs of the combinations provided by the proposed method tended to be
comparable to or somewhat better than the results from robust logistic regression. In all scenarios,
all three methods controlled the FPR, particularly as sample size increased. In addition to demon-
strating feasibility of our approach, these simulations highlight the fact that logistic regression is
relatively robust to violations of the linear-logistic model (e.g., nonlinear biomarker combinations
and deviations from the logit link).
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Table 3: Fitted combinations of the scaled predictors in the diabetes study. GLM, standard logistic
regression; rGLM, robust logistic regression; sTPR, proposed method with t = 0.10.
Predictor GLM rGLM sTPR
Number of pregnancies 0.321 0.320 0.403
Plasma glucose 0.793 0.792 0.627
Blood pressure −0.077 −0.073 −0.026
Skin fold thickness 0.089 0.090 −0.146
Body mass index 0.399 0.400 0.609
Diabetes pedigree 0.280 0.281 0.191
Age 0.133 0.134 0.123
4.4 Convergence
In most simulation settings, convergence of the proposed method was achieved in more than 96% of
simulations. For some of the more extreme outlier scenarios considered in Section 4.3, convergence
failed in up to 7.3% of simulations.
5 Application to Diabetes Data
We applied the method we have developed to a study of diabetes in women with Pima Indian
heritage (Smith et al., 1988). We considered seven predictors measured in this study: number of
pregnancies, plasma glucose concentration, diastolic blood pressure, triceps skin fold thickness, body
mass index, age, and diabetes pedigree function (a measure of family history of diabetes (Smith
et al., 1988)). We used 332 observations as training data and reserved the remaining 200 observa-
tions for testing. The training and test datasets had 109 and 68 diabetes cases, respectively. We
scaled the variables to have equal variance. The distribution of predictors is depicted in Appendix
E. The combinations were fitted using the training data and evaluated using the test data. We
fixed the acceptable FPR at t = 0.10. We used logistic regression, robust logistic regression, and
the proposed method to construct the combinations, giving the results in Table 3, where the fitted
combinations from logistic regression and robust logistic regression have been normalized to aid in
comparison.
Using thresholds based on an FPR of 10% in the test data, the estimated TPR in the test data
was 54.4% for both logistic regression and robust logistic regression, and 55.9% for the proposed
method. The estimated FPR in the test data using thresholds corresponding to an FPR of 10% in
the training data was 18.2% for both logistic regression and robust logistic regression and 26.5%
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for the proposed method. The fact that these FPRs exceeded the target value for all three methods
indicates potentially important differences in the controls between the training and test data.
6 Discussion
We have proposed a distribution-free method for constructing linear biomarker combinations by
maximizing a smooth approximation to the TPR while constraining a smooth approximation to
the FPR. Ours is the first distribution-free approach targeting the TPR for a specified FPR that
can be used with more than two or three biomarkers. While we do not expect our method to
outperform every other approach in every dataset, we have demonstrated broad feasibility of our
method and, importantly, we have identified scenarios where the performance of our method is
superior to alternative approaches.
The proposed method could be adapted to minimize the FPR while controlling the TPR to be
above some acceptable level. Since the TPR and FPR condition on disease status, the proposed
method can be used with case-control data. For case-control data matched on a covariate, however,
it becomes necessary to consider the covariate-adjusted ROC curve and corresponding covariate-
adjusted summaries, and thus the methods presented here are not immediately applicable (Janes
and Pepe, 2008).
As our smooth approximation function is non-convex, the choice of starting values should be
considered further. Extensions of convex methods, such as the ramp function method proposed
by Fong, Yin, and Huang (2016) for the AUC, could also be considered. The idea of partitioning the
search space, proposed by Yan et al. (2018), may also be useful. Further research could investigate
methods for evaluating the true and false positive rates of biomarker combinations after estimation,
for example, sample-splitting, bootstrapping, or k-fold cross-validation.
7 Software
An R package containing code to implement the proposed method, maxTPR, is publicly available via
CRAN.
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Appendix A
Proposition 1. If the biomarkers (X1, X2) are conditionally multivariate normal with proportional
covariance matrices given D, that is,
(X1, X2 | D = 0) ∼ N(µ0,Σ), (X1, X2 | D = 1) ∼ N(µ1, σ2Σ),
then the optimal biomarker combination in the sense of the ROC curve is of the form
β0 + β1X1 + β2X2 + β3X1X2 + β4X
2
1 + β5X
2
2
for some vector (β0, β1, β2, β3, β4, β5) ∈ R5.
Proof. It is known that the optimal combination of (X1, X2) in terms of the ROC curve is the
likelihood ratio, f(X1, X2 | D = 1)/f(X1, X2 | D = 0), or any monotone increasing function
thereof (McIntosh and Pepe, 2002). Let M = (X1, X2). Without loss of generality, let µ0 = 0 and
µ1 = µ = (µX1 , µX2). Then
f(M | D = 1)
f(M | D = 0) =
|σ2Σ|−1/2exp{−12(M − µ)>(σ2Σ)−1(M − µ)}
|Σ|−1/2exp{−12M>Σ−1M}
=
exp
{−12(M − µ)>(σ2Σ)−1(M − µ)}
σ2exp
{−12M>Σ−1M}
=
1
σ2
exp
{
−(M − µ)
>Σ−1(M − µ)
2σ2
+
M>Σ−1M
2
}
.
Denote the entries of Σ−1 by
Σ−1 =
 S11 S12
S21 S22
 .
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Then, we can write that
− 1
2σ2
(M − µ)>Σ−1(M − µ) + 1
2
M>Σ−1M
=
1
2
[
1
σ2
{−S11(X21 − 2X1µX1 + µ2X1)− S21(X1X2 −X2µX1 −X1µX2 + µX1µX2)
−S12(X1X2 −X1µX2 −X2µX1 + µX1µX2)− S22(X22 − 2X2µX2 + µ2X2)
}
+ S11X
2
1 + S21X1X2 + S12X1X2 + S22X
2
2
]
=
1
2
{(
S11 − S11
σ2
)
X21 +
(
S22 − S22
σ2
)
X22 +
(
S12 + S21 − S12
σ2
− S21
σ2
)
X1X2
+
(
2S11µX1 + S21µX2 + S12µX2
σ2
)
X1 +
(
S21µX1 + S12µX1 + 2S22µX2
σ2
)
X2
+
−S11µ2X1 − S21µX1µX2 − S12µX1µX2 − S22µ2X2
σ2
}
= β0 + β1X1 + β2X2 + β3X1X2 + β4X
2
1 + β5X
2
2
as claimed, where
β0 =
−S11µ2X1 − S21µX1µX2 − S12µX1µX2 − S22µ2X2
σ2
β1 =
(
2S11µX1 + S21µX2 + S12µX2
σ2
)
β2 =
(
S21µX1 + S12µX1 + 2S22µX2
σ2
)
β3 =
(
S12 + S21 − S12
σ2
− S21
σ2
)
β4 =
(
S11 − S11
σ2
)
β5 =
(
S22 − S22
σ2
)
.
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Appendix B
The proof of Theorem 1 relies on Lemmas 1 and 2, which are stated and proved below.
Lemma 1. Say that a bounded function f : Rd → R and possibly random sets Ω0,Ω1,Ω2, . . . ⊆ Rd
are given, and let {an}n≥1 be a decreasing sequence of positive real numbers tending to zero. For each
n ≥ 1, suppose that ω0,n ∈ Ω0 and ωn ∈ Ωn are near-maximizers of f over Ω0 and Ωn, respectively,
in the sense that f(ω0,n) ≥ supω∈Ω0 f(ω)− an and f(ωn) ≥ supω∈Ωn f(ω)− an. Further, define
dn = sup
ω∈Ωn
inf
ω˜∈Ω0
d(ω, ω˜), en = sup
ω∈Ω0
inf
ω˜∈Ωn
d(ω, ω˜),
where d is the Euclidean distance in Rd. If dn and en tend to zero almost surely, and f is globally
Lipschitz continuous, then |f(ω0,n)− f(ωn)| tends to zero almost surely. In particular, this implies
that ∣∣∣∣ sup
ω∈Ω0
f(ω)− sup
ω∈Ωn
f(ω)
∣∣∣∣ −→ 0
almost surely.
Proof. Say that both dn and en tend to zero almost surely, and denote by K > 0 the Lipschitz
constant of f . Suppose that for some  > 0 we have that
P
{
lim sup
n
|f(ωn)− f(ω0,n)| > 
}
> 0 .
We will show that this leads to a contradiction, and thus that it must be true that
P{lim supn |f(ωn)− f(ω0,n)| > } = 0 for each  > 0, thus establishing the desired result.
On a set of probability one, there exists an n ≥ 1 such that, for each n ≥ n, there exists ω∗n ∈ Ω0
and ω∗0,n ∈ Ωn satisfying d(ω∗n, ωn) < /(2K) and d(ω∗0,n, ω0,n) < /(2K). Then, on this same set,
for n ≥ n, |f(ω∗n) − f(ωn)| ≤ /2 and |f(ω∗0,n) − f(ω0,n)| ≤ /2, so that f(ω0,n) ≤ f(ω∗0,n) + /2
and f(ωn) ≤ f(ω∗n) + /2 in particular. Since ω∗0,n ∈ Ωn and ω∗n ∈ Ω0, it must also be true that
f(ω∗0,n) ≤ f(ωn)+an and f(ω∗n) ≤ f(ω0,n)+an. This then implies that |f(ω0,n)−f(ωn)| ≤ /2+an
for all n ≥ n on a set of probability one. Since an tends to zero deterministically, this yields the
sought contradiction.
To establish the last portion of the Lemma, we simply use the first part along with the fact that
∣∣∣∣ sup
ω∈Ωn
f(ω)− sup
ω∈Ω0
f(ω)
∣∣∣∣ ≤ |f(ω0,n)− f(ωn)|+ 2an .
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Lemma 2. Under conditions (1)–(5), we have that
sup
(θ,δ)∈Ω
∣∣∣ ˜FPRn0(θ, δ)− FPR(θ, δ)∣∣∣ −→ 0, sup
(θ,δ)∈Ω
∣∣∣ ˜TPRn1(θ, δ)− TPR(θ, δ)∣∣∣ −→ 0
almost surely as n tends to +∞, where Ω = {(θ, δ) ∈ Rp × R : ||θ|| = 1}.
Proof. We prove the claim for the false positive rate (FPR); the proof for the true positive rate
(TPR) is analogous. We can write
sup
(θ,δ)∈Ω
∣∣∣ ˜FPRn0(θ, δ)− FPR(θ, δ)∣∣∣ ≤ sup
(θ,δ)∈Ω
∣∣∣ ˜FPRn0(θ, δ)− E{ ˜FPRn0(θ, δ)}∣∣∣
+ sup
(θ,δ)∈Ω
∣∣∣E{ ˜FPRn0(θ, δ)} − FPR(θ, δ)∣∣∣ .
First, we consider ˜FPRn0(θ, δ)− E{ ˜FPRn0(θ, δ)}. We can write this as
˜FPRn0(θ, δ)− E{ ˜FPRn0(θ, δ)} =
1
n0
n0∑
j=1
Φ
(
θ>X0j − δ
h
)
−
∫
Φ
(
θ>x− δ
h
)
dF0(x) .
The class of functions G1 = {(θ, δ) 7→ θ>x − δ : θ ∈ Rp, δ ∈ R,x ∈ Rp} is a Vapnik–Chervonenkis
(VC) class. Since u 7→ Φ(u/h) is monotone for each h > 0, the class of functions G2 = {(θ, δ) 7→
Φ{(θ>x − δ)/h} : θ ∈ Rp, δ ∈ R,x ∈ Rp, h > 0} is also VC (Kosorok, 2008; van der Vaart, 1998;
van der Vaart and Wellner, 2000). Since the constant 1 is an applicable envelope function for this
class, G2 is F0–Glivenko-Cantelli, giving that (Kosorok, 2008; van der Vaart and Wellner, 2000)
sup
(θ,δ)∈Ω
∣∣∣ ˜FPRn0(θ, δ)− E{ ˜FPRn0(θ, δ)}∣∣∣ −→ 0
almost surely.
Next, we consider E{ ˜FPRn0(θ, δ)} − FPR(θ, δ). We can write this as
E{ ˜FPRn0(θ, δ)} − FPR(θ, δ) =
∫
Φ
(
θ>x− δ
h
)
dF0(x)− P (θ>X > δ | D = 0).
For a general random variable V with distribution function F that is Lipschitz continuous, say with
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constant M > 0, we can write
E
{
Φ
(
s− V
h
)}
=
∫
Φ
(
s− v
h
)
dF (v) = h
∫
Φ(u)f(s− hu)du
with u = (s− v)/h. Using integration by parts and Lemma 2.1 from Winter (1979), this becomes
h
∫
Φ(u)f(s− hu)du =
∫
φ(u)F (s− hu)du ,
and so, we find that∣∣∣∣E{Φ(s− Vh
)}
− F (s)
∣∣∣∣ = ∣∣∣∣∫ φ(u)F (s− hu)du− F (s)∣∣∣∣
≤
∫
|F (s− hu)− F (s)|φ(u)du
≤ M
∫
|hu|φ(u)du = Mh
(
2
pi
)1/2
.
Since h tends to zero as n tends to infinity, this implies that
sup
s
∣∣∣∣E{Φ(s− Vh
)}
− F (s)
∣∣∣∣ = o(1) .
We now return to θ>X and consider the case p = 2, so that θ>X = θ1X1 + θ2X2. Let Y1 =
θ1X1 + θ2X2 and Y2 = θ2X2. Then, we have that fY1,Y2(y1, y2) = fX1,X2(x1, x2)|θ1θ2|−1, where
x1 = x1(y1, y2) = (y1 − y2)/θ1 and x2 = x2(y1, y2) = y2/θ2. We find that
∫
Φ
(
s− θ>x
h
)
dFX(x) =
∫
Φ
(
s− y1
h
)
dFY (y) =
∫
Φ
(
s− y1
h
)
dFY1(y1)
for any s ∈ R. Since P (θ>X ≤ δ | D = 0) = P (Y1 ≤ δ | D = 0), we can write
sup
(θ,δ)∈Ω
∣∣∣∣∣
∫
Φ
(
θ>x− δ
h
)
dF0(x)− P (θ>X > δ | D = 0)
∣∣∣∣∣
= sup
δ∈R
∣∣∣∣∫ Φ(y1 − δh
)
dFY1|D=0(y1)− P (Y1 > δ | D = 0)
∣∣∣∣
= sup
δ∈R
∣∣∣∣∫ Φ(δ − y1h
)
dFY1|D=0(y1)− P (Y1 ≤ δ | D = 0)
∣∣∣∣ ,
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implying, in view of condition (4) and the results above, that
sup
(θ,δ)∈Ω
∣∣∣∣∣
∫
Φ
(
θ>x− δ
h
)
dF0(x)− P (θ>X > δ | D = 0)
∣∣∣∣∣ = o(1) .
The result for p > 2 can be proved analogously.
Combining these results, we conclude that sup(θ,δ)∈Ω | ˜FPRn0(θ, δ) − FPR(θ, δ)| tends to zero
almost surely, as claimed.
Proof of Theorem 1. First, we show that lim supn FPR(θ˜t, δ˜t) ≤ t almost surely. We can write
FPR(θ˜t, δ˜t) = ˜FPRn0(θ˜t, δ˜t) + {FPR(θ˜t, δ˜t)− ˜FPRn0(θ˜t, δ˜t)}
≤ ˜FPRn0(θ˜t, δ˜t) + |FPR(θ˜t, δ˜t)− ˜FPRn0(θ˜t, δ˜t)|
≤ ˜FPRn0(θ˜t, δ˜t) + sup
(θ,δ)∈Ω
|FPR(θ, δ)− ˜FPRn0(θ, δ)| ≤ t+ sup
(θ,δ)∈Ω
|FPR(θ, δ)− ˜FPRn0(θ, δ)| .
As such, it follows that
P{lim sup
n
FPR(θ˜t, δ˜t) ≤ t} ≥ P{lim sup
n
sup
(θ,δ)∈Ω
|FPR(θ, δ)− ˜FPRn0(θ, δ)| = 0} = 1
in view of Lemma 2, thereby establishing the first part of the theorem.
Let t ∈ (0, 1) be fixed. We now establish that
∣∣∣∣TPR(θ˜t, δ˜t)− sup
(θ,δ)∈Ωt
TPR(θ, δ)
∣∣∣∣ −→ 0
almost surely. For convenience, denote (θ, δ) by ω. Consider the function f defined pointwise as
f(ω) = TPR(θ, δ), and set Ω0 = Ωt and Ωn = Ω˜t,n0 for each n ≥ 1. We verify that the conditions of
Lemma 1 hold for these particular choices. We have that f(ω) = TPR(θ, δ) is a bounded function.
We must show dn0 and en0 tend to zero almost surely, where
dn0 = sup
ω∈Ω˜t,n0
inf
ω˜∈Ωt
d(ω, ω˜), en0 = sup
ω∈Ωt
inf
ω˜∈Ω˜t,n0
d(ω, ω˜),
and d is the Euclidean distance in Rp+1. We consider dn0 first. Denote by Gθ the conditional
distribution function of θ>X given D = 0. By assumption, the corresponding conditional quantile
function, denoted by G−1θ , is uniformly Lipschitz continuous over {θ ∈ Rp : ‖θ‖ = 1}, say with
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constant C > 0 independent of θ. Suppose that, for some κ > 0, supω∈Ω˜t,n0 | ˜FPRn0(ω)−FPR(ω)| ≤
κ. Because it is true that
κ ≥ sup
ω∈Ω˜t,n0
| ˜FPRn0(ω)− FPR(ω)| ≥
∣∣∣∣ sup
ω∈Ω˜t,n0
˜FPRn0(ω)− sup
ω∈Ω˜t,n0
FPR(ω)
∣∣∣∣ ,
then supω∈Ω˜t,n0 FPR(ω) ≤ κ+ t, giving ˜FPRn0(ω) ≤ t and FPR(ω) ≤ κ+ t for each ω ∈ Ω˜t,n0 .
For any given ω = (θ, δ) ∈ Ω˜t,n0 , write t∗(ω) = Gθ(δ), giving t∗(ω) = FPR(ω) ≤ κ + t. If
t∗(ω) ≤ t, note also that ω ∈ Ωt and set ω∗ = ω. Otherwise, find δ∗ such that 1 − Gθ(δ∗) = t,
namely by taking δ∗ = G−1θ (1− t). Defining ω∗ = (θ, δ∗) ∈ Ωt, observe that
d(ω, ω∗) = |δ − δ∗| = |G−1θ (1− t∗(ω))−G−1θ (1− t)| ≤ C|t− t∗(ω)| ≤ Cκ .
Thus, for each ω ∈ Ω˜t,n0 , it is true that inf ω˜∈Ωt d(ω, ω˜) ≤ Cκ and therefore dn0 ≤ Cκ. As such, if
dn0 >  for some  > 0, then supω∈Ω˜t,n0 | ˜FPRn0(ω)−FPR(ω)| > κ for κ = /C. This implies that
P
(
sup
m≥n0
dm > 
)
≤ P
(
sup
m≥n0
sup
ω∈Ω˜t,m
| ˜FPRm(ω)− FPR(ω)| > κ
)
−→ 0
by Lemma 2. Thus, dn tends to zero almost surely since, for each  > 0,
P
(
lim sup
m
{dm ≥ }
)
≤ P
(
lim sup
m
dm ≥ 
)
= 0 .
Using similar arguments, we may show that en also tends to zero almost surely.
The fact that dn and en tend to zero almost surely implies, in view of Lemma 1, that we have
that | sup(θ,δ)∈Ωt TPR(θ, δ)− sup(θ,δ)∈Ω˜t,n0 TPR(θ, δ)| tends to zero almost surely. Combining this
with an application of Lemma 2, we have that
∣∣∣∣ sup
(θ,δ)∈Ωt
TPR(θ, δ) − sup
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ)
∣∣∣∣
≤
∣∣∣∣ sup
(θ,δ)∈Ωt
TPR(θ, δ)− sup
(θ,δ)∈Ω˜t,n0
TPR(θ, δ)
∣∣∣∣+ ∣∣∣∣ sup
(θ,δ)∈Ω˜t,n0
TPR(θ, δ)− sup
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ)
∣∣∣∣
≤
∣∣∣∣ sup
(θ,δ)∈Ωt
TPR(θ, δ)− sup
(θ,δ)∈Ω˜t,n0
TPR(θ, δ)
∣∣∣∣+ sup
(θ,δ)∈Ω˜t,n0
|TPR(θ, δ)− ˜TPRn1(θ, δ)| −→ 0
almost surely. Since |TPR(θ˜t, δ˜t) − ˜TPRn1(θ˜t, δ˜t)| ≤ sup(θ,δ)∈Ω |TPR(θ, δ) − ˜TPRn1(θ, δ)| and,
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by Lemma 2, sup(θ,δ)∈Ω |TPR(θ, δ) − ˜TPRn1(θ, δ)| tends to zero almost surely, |TPR(θ˜t, δ˜t) −
˜TPRn1(θ˜t, δ˜t)| tends to zero almost surely. In addition, since (θ˜t, δ˜t) is a near-maximizer of ˜TPRn1 ,
sup(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ) ≤ ˜TPRn1(θ˜t, δ˜t) + an, giving
∣∣∣∣ sup
(θ,δ)∈Ωt
TPR(θ, δ)− TPR(θ˜t, δ˜t)
∣∣∣∣
≤
∣∣∣∣ sup
(θ,δ)∈Ωt
TPR(θ, δ)− sup
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ)
∣∣∣∣+ ∣∣∣∣ sup
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ)− TPR(θ˜t, δ˜t)
∣∣∣∣
≤
∣∣∣∣ sup
(θ,δ)∈Ωt
TPR(θ, δ)− sup
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ)
∣∣∣∣+ ∣∣∣∣ sup
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ)− ˜TPRn1(θ˜t, δ˜t)
∣∣∣∣
+
∣∣∣∣ ˜TPRn1(θ˜t, δ˜t)− TPR(θ˜t, δ˜t)∣∣∣∣
≤
∣∣∣∣ sup
(θ,δ)∈Ωt
TPR(θ, δ)− sup
(θ,δ)∈Ω˜t,n0
˜TPRn1(θ, δ)
∣∣∣∣+ an + ∣∣∣∣ ˜TPRn1(θ˜t, δ˜t)− TPR(θ˜t, δ˜t)∣∣∣∣ −→ 0
almost surely, completing the proof.
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Appendix C: Simulation results for data with outliers
Note: When simulating with outliers, the true biomarker combination was occasionally so large
that it returned a non-value for the outcome D; for example, with f1(v) = expit(v), this occurs in
R when v > 800. These observations had to be removed from the simulated dataset, though this
affected an extremely small fraction of observations.
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Table 4: Mean TPR and FPR and corresponding standard deviation (in parentheses) for f(v) =
f1(v) ≡ expit(v) = ev/(1 + ev) and β0 = 0 across 1000 simulations. The TPR is based on the
threshold corresponding to a FPR of t in the test data whereas the FPR is based on the thresholds
estimated in the training data. n, size of the training dataset; t, acceptable FPR; TPR, true positive
rate; FPR, false positive rate; GLM, standard logistic regression; rGLM, robust logistic regression;
sTPR, proposed method. All numbers are percentages.
Outliers n Measure Method
GLM rGLM sTPR
t = 0.05
Yes 200 TPR 12.2 (2.1) 13.6 (2.6) 13.4 (2.7)
FPR 5.7 (2.2) 5.9 (2.3) 6.4 (2.4)
400 TPR 12.1 (1.7) 14.1 (2.3) 13.9 (2.4)
FPR 5.4 (1.6) 5.4 (1.6) 5.9 (1.7)
800 TPR 11.8 (1.2) 14.4 (2.2) 14.4 (2.3)
FPR 5.1 (1.1) 5.2 (1.1) 5.5 (1.2)
No 200 TPR 18.3 (0.6) 18.3 (0.6) 17.8 (1.8)
FPR 5.5 (2.2) 5.5 (2.2) 6.2 (2.4)
400 TPR 18.5 (0.3) 18.5 (0.3) 18.1 (1.6)
FPR 5.3 (1.5) 5.3 (1.5) 5.7 (1.6)
800 TPR 18.6 (0.2) 18.6 (0.2) 18.4 (1.2)
FPR 5.2 (1.1) 5.2 (1.1) 5.5 (1.2)
t = 0.10
Yes 200 TPR 22.5 (3.8) 24.6 (4.3) 24.6 (4.2)
FPR 10.9 (3.1) 11.1 (3.0) 11.7 (3.2)
400 TPR 21.8 (2.8) 25.1 (4.0) 25.2 (4.0)
FPR 10.4 (2.0) 10.5 (2.1) 11.0 (2.1)
800 TPR 21.4 (2.0) 25.7 (3.6) 25.8 (3.6)
FPR 10.1 (1.5) 10.1 (1.5) 10.5 (1.5)
No 200 TPR 29.4 (0.8) 29.5 (0.8) 28.9 (2.2)
FPR 10.5 (3.1) 10.5 (3.1) 11.4 (3.2)
400 TPR 29.8 (0.4) 29.8 (0.4) 29.5 (1.3)
FPR 10.4 (2.1) 10.4 (2.1) 10.9 (2.2)
800 TPR 29.9 (0.2) 29.9 (0.2) 29.7 (1.5)
FPR 10.2 (1.5) 10.2 (1.5) 10.6 (1.5)
t = 0.20
Yes 200 TPR 38.0 (5.1) 40.8 (5.8) 41.0 (5.7)
FPR 20.9 (4.0) 21.1 (4.0) 21.8 (4.0)
400 TPR 37.4 (3.9) 41.7 (5.3) 41.9 (5.2)
FPR 20.5 (2.8) 20.6 (2.9) 21.1 (2.9)
800 TPR 36.9 (2.9) 42.4 (4.6) 43.0 (4.4)
FPR 20.2 (2.0) 20.4 (2.0) 20.7 (2.0)
No 200 TPR 46.1 (0.9) 46.1 (0.9) 45.7 (1.5)
FPR 20.7 (4.1) 20.8 (4.1) 21.7 (4.2)
400 TPR 46.4 (0.5) 46.4 (0.5) 46.2 (0.8)
FPR 20.3 (2.8) 20.3 (2.8) 21.0 (2.8)
800 TPR 46.5 (0.2) 46.5 (0.3) 46.4 (0.6)
FPR 20.1 (2.0) 20.1 (2.0) 20.5 (2.0)
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Table 5: Mean TPR and FPR and corresponding standard deviation (in parentheses) for f(v) =
f2(v) ≡ 1(v < 0)× (1 + e−v/3)−1 + 1(v ≥ 0)× (1 + e−3v)−1 and β0 = 0 across 1000 simulations. The
TPR is based on the threshold corresponding to a FPR of t in the test data whereas the FPR is
based on the thresholds estimated in the training data. n, size of the training dataset; t, acceptable
FPR; TPR, true positive rate; FPR, false positive rate; GLM, standard logistic regression; rGLM,
robust logistic regression; sTPR, proposed method. All numbers are percentages.
Outliers n Measure Method
GLM rGLM sTPR
t = 0.05
Yes 200 TPR 20.2 (7.3) 26.4 (9.1) 27.7 (9.2)
FPR 5.9 (2.6) 6.0 (2.6) 6.5 (2.8)
400 TPR 19.0 (5.9) 27.6 (8.5) 29.3 (8.2)
FPR 5.5 (1.8) 5.5 (1.7) 5.8 (1.8)
800 TPR 17.9 (4.1) 29.4 (7.5) 30.8 (7.3)
FPR 5.3 (1.3) 5.3 (1.2) 5.5 (1.3)
No 200 TPR 37.9 (1.7) 37.8 (1.9) 37.5 (3.1)
FPR 5.8 (2.7) 5.7 (2.7) 6.5 (2.9)
400 TPR 38.6 (0.9) 38.5 (1.0) 38.3 (2.1)
FPR 5.3 (1.8) 5.3 (1.8) 5.8 (1.8)
800 TPR 38.9 (0.4) 38.9 (0.5) 38.6 (2.2)
FPR 5.2 (1.3) 5.2 (1.3) 5.5 (1.3)
t = 0.10
Yes 200 TPR 31.1 (8.9) 37.4 (10.8) 39.3 (11.0)
FPR 11.0 (3.5) 11.3 (3.6) 12.0 (3.6)
400 TPR 30.3 (7.1) 39.9 (9.8) 41.5 (9.6)
FPR 10.5 (2.5) 10.7 (2.4) 11.0 (2.5)
800 TPR 28.9 (5.0) 41.1 (8.9) 43.1 (8.6)
FPR 10.1 (1.7) 10.3 (1.7) 10.6 (1.8)
No 200 TPR 48.2 (1.8) 48.0 (1.9) 48.2 (2.0)
FPR 10.9 (3.5) 10.9 (3.5) 11.7 (3.6)
400 TPR 48.8 (0.9) 48.7 (1.0) 48.7 (1.1)
FPR 10.4 (2.4) 10.4 (2.4) 10.9 (2.5)
800 TPR 49.2 (0.4) 49.1 (0.5) 49.0 (0.6)
FPR 10.2 (1.7) 10.2 (1.7) 10.7 (1.8)
t = 0.20
Yes 200 TPR 45.0 (8.1) 50.4 (9.8) 51.9 (9.7)
FPR 21.2 (4.6) 21.5 (4.7) 22.0 (4.8)
400 TPR 44.4 (6.3) 52.8 (8.6) 54.0 (8.5)
FPR 20.4 (3.2) 20.8 (3.3) 21.2 (3.4)
800 TPR 44.1 (4.8) 54.8 (7.3) 56.5 (6.6)
FPR 20.2 (2.3) 20.3 (2.3) 20.7 (2.3)
No 200 TPR 59.5 (1.3) 59.4 (1.4) 59.3 (1.8)
FPR 21.1 (4.6) 21.1 (4.6) 22.1 (4.7)
400 TPR 60.0 (0.6) 59.9 (0.7) 59.8 (0.9)
FPR 20.5 (3.4) 20.6 (3.4) 21.2 (3.4)
800 TPR 60.2 (0.4) 60.1 (0.4) 60.1 (0.5)
FPR 20.3 (2.2) 20.3 (2.2) 20.7 (2.3)
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Table 6: Mean TPR and FPR and corresponding standard deviation (in parentheses) in the test
data for f(v) = f1(v) ≡ expit(v) = ev/(1 + ev) and β0 = −1.75 across 1000 simulations. The TPR
is based on the threshold corresponding to a FPR of t in the test data whereas the FPR is based
on the thresholds estimated in the training data. n, size of the training dataset; t, acceptable FPR;
TPR, true positive rate; FPR, false positive rate; GLM, standard logistic regression; rGLM, robust
logistic regression; sTPR, proposed method. All numbers are percentages.
Outliers n Measure Method
GLM rGLM sTPR
t = 0.05
Yes 200 TPR 13.0 (2.8) 13.4 (3.4) 13.5 (3.4)
FPR 5.3 (1.7) 5.4 (1.7) 5.7 (1.8)
400 TPR 12.7 (1.9) 13.4 (2.7) 13.6 (2.9)
FPR 5.2 (1.2) 5.2 (1.2) 5.4 (1.2)
800 TPR 12.5 (1.3) 13.2 (2.1) 13.6 (2.5)
FPR 5.1 (0.8) 5.2 (0.8) 5.2 (0.9)
No 200 TPR 18.1 (1.0) 18.1 (1.1) 17.5 (2.2)
FPR 5.5 (1.8) 5.5 (1.8) 5.9 (1.8)
400 TPR 18.5 (0.6) 18.5 (0.6) 18.2 (1.6)
FPR 5.1 (1.2) 5.2 (1.2) 5.4 (1.3)
800 TPR 18.7 (0.3) 18.7 (0.3) 18.5 (1.1)
FPR 5.1 (0.9) 5.1 (0.9) 5.3 (0.9)
t = 0.10
Yes 200 TPR 22.1 (4.5) 22.7 (5.3) 23.1 (5.3)
FPR 10.4 (2.4) 10.5 (2.4) 10.8 (2.4)
400 TPR 21.9 (3.6) 22.8 (4.7) 23.4 (4.8)
FPR 10.1 (1.7) 10.2 (1.7) 10.4 (1.8)
800 TPR 21.4 (2.3) 22.3 (3.4) 23.3 (4.3)
FPR 10.1 (1.2) 10.1 (1.2) 10.3 (1.2)
No 200 TPR 29.5 (1.3) 29.4 (1.3) 28.8 (2.5)
FPR 10.3 (2.3) 10.4 (2.3) 10.9 (2.3)
400 TPR 29.8 (0.7) 29.8 (0.7) 29.5 (1.5)
FPR 10.2 (1.7) 10.2 (1.7) 10.6 (1.7)
800 TPR 30.1 (0.4) 30.1 (0.4) 29.8 (1.1)
FPR 10.1 (1.1) 10.1 (1.1) 10.3 (1.1)
t = 0.20
Yes 200 TPR 36.4 (6.6) 37.2 (7.8) 38.1 (7.4)
FPR 20.5 (3.2) 20.6 (3.1) 21.0 (3.2)
400 TPR 36.2 (4.7) 37.3 (6.2) 38.5 (6.4)
FPR 20.1 (2.2) 20.2 (2.3) 20.4 (2.2)
800 TPR 35.7 (3.0) 37.0 (4.6) 38.8 (5.7)
FPR 20.2 (1.5) 20.2 (1.5) 20.4 (1.5)
No 200 TPR 46.1 (1.7) 46.1 (1.7) 45.5 (2.6)
FPR 20.4 (3.1) 20.5 (3.2) 21.0 (3.2)
400 TPR 46.7 (0.8) 46.7 (0.8) 46.4 (1.3)
FPR 20.1 (2.1) 20.2 (2.1) 20.5 (2.1)
800 TPR 47.0 (0.4) 47.0 (0.4) 46.8 (0.7)
FPR 20.0 (1.6) 20.0 (1.6) 20.2 (1.6)
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Table 7: Mean TPR and FPR and corresponding standard deviation (in parentheses) in the test
data for f(v) = f1(v) ≡ expit(v) = ev/(1 + ev) and β0 = 1.75 across 1000 simulations. The TPR is
based on the threshold corresponding to a FPR of t in the test data whereas the FPR is based on
the thresholds estimated in the training data. n, size of the training dataset; t, acceptable FPR;
TPR, true positive rate; FPR, false positive rate; GLM, standard logistic regression; rGLM, robust
logistic regression; sTPR, proposed method. All numbers are percentages.
Outliers n Measure Method
GLM rGLM sTPR
t = 0.05
Yes 200 TPR 8.4 (1.2) 8.4 (1.4) 8.2 (1.8)
FPR 7.3 (4.0) 6.9 (3.9) 7.7 (4.6)
400 TPR 8.6 (0.9) 8.5 (1.1) 8.3 (1.6)
FPR 6.3 (2.7) 6.3 (2.7) 6.7 (2.9)
800 TPR 8.7 (0.6) 8.6 (0.7) 8.5 (1.5)
FPR 5.8 (1.8) 5.8 (1.8) 6.1 (2.0)
No 200 TPR 18.7 (1.0) 18.7 (1.0) 17.2 (3.5)
FPR 6.3 (4.1) 6.1 (4.0) 7.4 (4.5)
400 TPR 19.0 (0.5) 19.0 (0.6) 17.9 (2.9)
FPR 5.7 (2.7) 5.6 (2.7) 6.4 (3.0)
800 TPR 19.2 (0.3) 19.2 (0.3) 18.3 (2.9)
FPR 5.3 (1.9) 5.3 (1.9) 5.9 (2.0)
t = 0.10
Yes 200 TPR 18.6 (3.9) 19.1 (4.7) 19.4 (4.8)
FPR 12.4 (5.1) 12.4 (5.0) 13.5 (5.4)
400 TPR 18.6 (2.5) 19.2 (3.5) 19.8 (3.8)
FPR 11.1 (3.4) 11.1 (3.5) 12.0 (3.7)
800 TPR 18.4 (1.4) 19.2 (2.6) 19.8 (3.4)
FPR 10.8 (2.6) 10.8 (2.6) 11.3 (2.7)
No 200 TPR 29.9 (1.3) 29.9 (1.3) 28.7 (3.6)
FPR 11.7 (5.2) 11.5 (5.2) 13.1 (5.6)
400 TPR 30.4 (0.6) 30.3 (0.7) 29.4 (3.4)
FPR 10.7 (3.6) 10.6 (3.6) 11.7 (3.8)
800 TPR 30.6 (0.3) 30.6 (0.3) 30.2 (2.0)
FPR 10.4 (2.5) 10.4 (2.5) 11.1 (2.5)
t = 0.20
Yes 200 TPR 34.2 (6.4) 34.9 (7.7) 35.9 (7.1)
FPR 22.5 (6.5) 22.7 (6.3) 24.0 (6.7)
400 TPR 34.2 (4.3) 35.0 (5.6) 36.3 (5.9)
FPR 21.4 (4.7) 21.5 (4.7) 22.4 (4.8)
800 TPR 33.9 (2.8) 35.0 (4.4) 36.2 (5.0)
FPR 20.6 (3.3) 20.7 (3.3) 21.3 (3.4)
No 200 TPR 46.4 (1.6) 46.4 (1.6) 45.6 (3.3)
FPR 22.2 (7.0) 22.0 (7.0) 23.9 (7.1)
400 TPR 47.0 (0.8) 47.0 (0.8) 46.5 (2.2)
FPR 20.8 (5.0) 20.7 (4.9) 22.0 (5.0)
800 TPR 47.2 (0.4) 47.2 (0.4) 46.9 (1.9)
FPR 20.6 (3.4) 20.6 (3.4) 21.4 (3.5)
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Table 8: Mean TPR and FPR and corresponding standard deviation (in parentheses) in the test
data for f(v) = f2(v) ≡ 1(v < 0)×(1/(1+e−v/3))+1(v ≥ 0)×(1/(1+e−3v)) and β0 = −5.25 across
1000 simulations. The TPR is based on the threshold corresponding to a FPR of t in the test data
whereas the FPR is based on the thresholds estimated in the training data. n, size of the training
dataset; t, acceptable FPR; TPR, true positive rate; FPR, false positive rate; GLM, standard
logistic regression; rGLM, robust logistic regression; sTPR, proposed method. All numbers are
percentages.
Outliers n Measure Method
GLM rGLM sTPR
t = 0.05
Yes 200 TPR 7.1 (1.1) 7.1 (1.1) 7.1 (1.1)
FPR 5.7 (1.8) 5.7 (1.8) 5.9 (1.9)
400 TPR 7.4 (1.0) 7.3 (0.9) 7.3 (1.0)
FPR 5.3 (1.2) 5.4 (1.2) 5.5 (1.2)
800 TPR 7.6 (0.8) 7.5 (0.8) 7.5 (0.9)
FPR 5.1 (0.8) 5.2 (0.8) 5.2 (0.9)
No 200 TPR 7.3 (1.4) 7.3 (1.4) 7.2 (1.4)
FPR 5.5 (1.7) 5.6 (1.7) 5.9 (1.8)
400 TPR 7.8 (0.9) 7.8 (1.0) 7.7 (1.1)
FPR 5.2 (1.2) 5.2 (1.1) 5.4 (1.2)
800 TPR 8.1 (0.4) 8.1 (0.4) 8.0 (0.7)
FPR 5.1 (0.9) 5.1 (0.9) 5.2 (0.9)
t = 0.10
Yes 200 TPR 12.4 (2.0) 12.3 (2.0) 12.4 (2.0)
FPR 10.6 (2.3) 10.6 (2.3) 10.9 (2.4)
400 TPR 12.6 (1.7) 12.4 (1.7) 12.6 (1.8)
FPR 10.4 (1.7) 10.4 (1.7) 10.6 (1.7)
800 TPR 12.8 (1.5) 12.5 (1.5) 12.7 (1.6)
FPR 10.2 (1.2) 10.2 (1.1) 10.3 (1.2)
No 200 TPR 13.9 (2.2) 13.9 (2.2) 13.6 (2.3)
FPR 10.7 (2.3) 10.8 (2.3) 11.2 (2.4)
400 TPR 14.5 (1.5) 14.5 (1.5) 14.4 (1.6)
FPR 10.2 (1.6) 10.2 (1.6) 10.5 (1.6)
800 TPR 15.0 (0.8) 15.0 (0.8) 14.9 (1.0)
FPR 10.2 (1.2) 10.2 (1.2) 10.4 (1.2)
t = 0.20
Yes 200 TPR 22.4 (3.6) 22.2 (3.7) 22.5 (3.7)
FPR 20.9 (3.1) 20.9 (3.2) 21.3 (3.2)
400 TPR 22.6 (3.3) 22.3 (3.3) 22.7 (3.3)
FPR 20.6 (2.2) 20.6 (2.2) 20.9 (2.2)
800 TPR 22.8 (2.7) 22.3 (2.8) 22.8 (2.8)
FPR 20.2 (1.5) 20.2 (1.6) 20.4 (1.6)
No 200 TPR 25.8 (3.5) 25.7 (3.5) 25.5 (3.6)
FPR 20.9 (3.1) 20.9 (3.1) 21.4 (3.1)
400 TPR 26.9 (2.3) 26.9 (2.3) 26.8 (2.3)
FPR 20.5 (2.1) 20.5 (2.1) 20.8 (2.1)
800 TPR 27.7 (1.1) 27.7 (1.1) 27.5 (1.3)
FPR 20.3 (1.6) 20.3 (1.6) 20.5 (1.6)
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Table 9: Mean TPR and FPR and corresponding standard deviation (in parentheses) in the test
data for f(v) = f2(v) ≡ 1(v < 0)× (1/(1 + e−v/3)) + 1(v ≥ 0)× (1/(1 + e−3v)) and β0 = 0.6 across
1000 simulations. The TPR is based on the threshold corresponding to a FPR of t in the test data
whereas the FPR is based on the thresholds estimated in the training data. n, size of the training
dataset; t, acceptable FPR; TPR, true positive rate; FPR, false positive rate; GLM, standard
logistic regression; rGLM, robust logistic regression; sTPR, proposed method. All numbers are
percentages.
Outliers n Measure Method
GLM rGLM sTPR
t = 0.05
Yes 200 TPR 23.0 (8.6) 30.5 (10.9) 31.9 (10.8)
FPR 6.4 (3.3) 6.3 (3.4) 6.8 (3.7)
Yes 400 TPR 21.5 (6.9) 31.8 (10.5) 33.5 (10.1)
FPR 5.8 (2.3) 5.8 (2.4) 6.2 (2.6)
Yes 800 TPR 20.0 (4.4) 34.6 (9.2) 35.8 (8.5)
FPR 5.4 (1.6) 5.3 (1.6) 5.7 (1.7)
No 200 TPR 49.7 (1.5) 49.5 (1.7) 48.6 (4.4)
FPR 6.0 (3.5) 5.9 (3.5) 6.8 (3.7)
No 400 TPR 50.3 (0.7) 50.1 (0.8) 49.7 (2.3)
FPR 5.5 (2.5) 5.4 (2.5) 6.1 (2.6)
No 800 TPR 50.5 (0.4) 50.5 (0.5) 50.1 (2.0)
FPR 5.2 (1.6) 5.2 (1.6) 5.6 (1.7)
t = 0.10
Yes 200 TPR 37.3 (11.0) 45.7 (13.7) 48.4 (13.2)
FPR 11.5 (4.5) 11.6 (4.5) 12.4 (4.6)
Yes 400 TPR 35.2 (8.5) 47.5 (12.9) 50.6 (12.1)
FPR 10.8 (3.1) 10.9 (3.2) 11.4 (3.3)
Yes 800 TPR 34.5 (6.6) 51.3 (10.7) 53.6 (10.2)
FPR 10.4 (2.2) 10.4 (2.2) 10.8 (2.3)
No 200 TPR 61.3 (1.4) 61.1 (1.6) 60.7 (3.2)
FPR 10.9 (4.5) 10.9 (4.5) 12.1 (4.7)
No 400 TPR 61.8 (0.7) 61.6 (0.8) 61.4 (1.2)
FPR 10.6 (3.2) 10.6 (3.2) 11.4 (3.3)
No 800 TPR 62.0 (0.4) 62.0 (0.4) 61.8 (0.8)
FPR 10.3 (2.3) 10.3 (2.3) 10.9 (2.4)
t = 0.20
Yes 200 TPR 53.2 (10.6) 60.9 (13.0) 64.2 (12.3)
FPR 21.2 (5.9) 21.8 (6.0) 22.8 (6.0)
Yes 400 TPR 52.0 (8.5) 63.5 (11.8) 65.4 (11.3)
FPR 20.7 (4.1) 21.1 (4.2) 21.7 (4.1)
Yes 800 TPR 51.1 (6.0) 66.3 (9.7) 68.6 (8.2)
FPR 20.4 (3.0) 20.6 (3.0) 21.1 (3.0)
No 200 TPR 73.3 (1.1) 73.1 (1.3) 73.0 (1.5)
FPR 21.4 (6.4) 21.4 (6.4) 22.5 (6.3)
No 400 TPR 73.6 (0.6) 73.5 (0.7) 73.5 (0.8)
FPR 20.7 (4.4) 20.7 (4.4) 21.6 (4.4)
No 800 TPR 73.8 (0.3) 73.8 (0.4) 73.8 (0.4)
FPR 20.4 (3.0) 20.4 (3.0) 21.0 (3.0)
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Appendix D: Illustration of data simulated with outliers
Figure: Datasets with f(v) = f1(v) ≡ expit(v), β0 = 0, without (left plot) and with outliers (right
plot). Cases are represented by red circles, and controls are represented by blue triangles. The plot
with outliers also includes an ellipse (dashed black line) indicating the 99% confidence region for
the distribution of (X1, X2) without outliers.
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Appendix E: Biomarker distribution in Pima Indian diabetes dataset
Figure: Stratified distributions of the scaled predictors measured in the diabetes study for the
observations in the training data. The predictors are number of pregnancies, plasma glucose con-
centration, diastolic blood pressure, triceps skin fold thickness, body mass index, diabetes pedigree
function, and age. The predictor values are shown on the x-axis of each plot. The red solid line
represents the distribution among diabetes cases and the blue dotted line represents the distribution
among controls.
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